Can a digital health program really improve health outcomes for mothers and babies within a year?

Few questions matter more to grant-making bodies and field researchers than whether a maternal and child health program can show movement on the metrics that count inside a single funding cycle. The pressure is real: donors increasingly ask for evidence of change within twelve months, while the underlying outcomes (facility delivery, neonatal survival, immunization completeness) are slow-moving by nature. Understanding maternal child health technology impact means separating the indicators that genuinely shift inside a year from those that take a generation to move, and being honest about which is which when a proposal lands on a review committee's desk.

A May 2024 systematic review of 131 randomized and quasi-experimental studies found that mHealth strategies reliably increased antenatal clinic attendance and improved the timeliness of child immunization, while their effect on facility-based delivery and infant feeding remained inconclusive.

What maternal child health technology impact looks like in twelve months

The honest answer to whether a digital health program can improve outcomes within a year is: it depends entirely on which outcome you measure. Maternal child health technology impact is not a single number. It is a chain of behaviors and events, each with its own response time. Process indicators such as antenatal care (ANC) attendance, screening coverage, and referral completion can move within weeks of deployment because they depend on contact frequency and reminders. Mortality outcomes, by contrast, are statistically rare events that require large sample sizes and longer observation windows before any change becomes detectable.

This distinction is where many programs and their evaluators talk past each other. A funder may want a reduction in neonatal mortality, but the program's data within twelve months will more credibly show a rise in fourth-visit ANC completion or a shorter median time from danger-sign detection to referral. Both are real. Only one is realistically measurable in a year.

The systematic review by researchers examining mHealth interventions from conception to 24 months postpartum in low- and middle-income countries (published in 2024) makes this concrete. Antenatal attendance and immunization timing responded; delivery location and feeding practices did not show consistent effects. The lesson for proposal design is to align the headline claim with the indicator that the deployment timeline can actually support.

Outcome indicator	Typical response time	Measurable within 12 months?	Sample size needed
ANC visit attendance	Weeks to months	Yes, with strong baseline	Moderate
Screening coverage	Weeks	Yes	Moderate
Referral completion rate	Weeks to months	Yes	Moderate
Immunization timeliness	Months	Yes, partially	Moderate to large
Facility-based delivery	6 to 18 months	Sometimes	Large
Neonatal mortality	18+ months	Rarely	Very large
Maternal mortality	Years	No	Very large

The pattern is clear. Programs reporting credible one-year results lead with contact and coverage metrics, treat delivery rates as a stretch indicator, and frame mortality as a long-horizon hypothesis rather than a twelve-month deliverable.

Why some indicators move quickly and others do not

The mechanics behind early movement are not mysterious. The interventions that shift fastest share a few features:

• They increase the frequency of contact between a pregnant woman and a health worker, usually through reminders or scheduled check-ins.
• They reduce friction at a specific decision point, such as recognizing a danger sign or completing a referral.
• They generate a data trail that lets supervisors correct gaps in near real time rather than at quarterly review.
• They target behaviors the household already controls, like attending a scheduled visit, rather than outcomes mediated by clinical capacity or supply chains.

Indicators that resist quick change tend to depend on factors outside the program's direct reach: the availability of a skilled birth attendant, the distance to an equipped facility, the presence of emergency obstetric care, or the rarity of the event itself. A reminder system can get a mother to the clinic door, but it cannot stock the clinic with magnesium sulfate.

Industry Applications

Antenatal engagement and early screening

The most documented short-term win is antenatal care attendance. A randomized evaluation in Kenya of a digital health platform improved women's knowledge and care-seeking behavior across the antenatal and postnatal periods, along with newborn care practices. In North-Western Burundi, a digitalized antenatal program reported in 2023 used mobile phone reminders to raise attendance in a rural setting, with early lessons published while the program was still maturing. These are exactly the kinds of process outcomes that appear inside a single year.

Community health worker triage

When community health workers carry digital tools into the field, the measurable change is often in triage speed and referral follow-through. Coverage expands because a worker can register and screen many households in a day, and the data feeds a supervisor who can spot incomplete referrals before they become missed ones. This is where contactless and phone-based vitals capture is being trialed, allowing a worker to record a screening signal without unpacking equipment that rural clinics rarely have.

Postnatal and newborn follow-up

Postnatal contact is historically the weakest link in the continuum of care, and it is also where digital reminders show early promise. Scheduled follow-up prompts for the first weeks of a newborn's life can lift the share of mothers who return for a postnatal check, a metric that responds within months even when mortality does not.

Current research and evidence

The evidence base has matured enough to support cautious claims and to puncture inflated ones. The 2024 systematic review covering 131 studies remains the most comprehensive synthesis, and its split verdict (positive for ANC attendance and immunization timing, inconclusive for delivery and feeding) is the most defensible summary available. A separate systematic literature review of mHealth interventions to reduce maternal and child mortality across Sub-Saharan Africa and Southern Asia found positive effects on antenatal attendance but treated mortality reduction as a longer-term and less consistently demonstrated outcome.

A 2024 editorial in Frontiers on mobile health interventions for maternal health emphasized that results depend heavily on design: user-centered, culturally grounded, and inclusive approaches are far more likely to reach vulnerable subgroups such as refugees and survivors of domestic violence. Larger health-system investments, including World Bank programs strengthening mobile health for hard-to-reach populations in Morocco and Tunisia with activities running into 2025, suggest that funders are betting on the model while still demanding rigorous outcome tracking.

The methodological caution that runs through this literature is consistent. Neonatal mortality reduction as a primary endpoint within a single RCT year is rare for a reason: the statistical power required is enormous, and confounding from parallel health-system changes is hard to rule out. Researchers who promise mortality movement in twelve months are usually overpromising. Those who report attendance, coverage, and referral metrics, with mortality as a downstream hypothesis, are on firmer ground.

The Future of maternal and child health technology

The next phase of work is likely to focus on three things. First, better short-horizon proxy indicators that correlate with long-term survival, so a one-year evaluation can credibly forecast multi-year impact. Second, stronger linkage between village-level screening data and national surveillance, so program effects can be observed at scale rather than in isolated cohorts. Third, equity-disaggregated reporting, because aggregate gains can hide stagnation among the most vulnerable women, which is precisely the group most programs claim to serve.

For grant-making bodies, the practical shift is toward funding designs that pre-register their measurable twelve-month outcomes separately from their aspirational long-term goals. That separation protects both the funder and the program from the credibility damage that follows an overstated mortality claim. The realistic promise of maternal child health technology impact within a year is meaningful and documentable, as long as the claim matches the clock.

Frequently asked questions

Can a digital health program reduce neonatal mortality within one year?

Rarely, and almost never as a statistically robust primary endpoint. Neonatal and maternal mortality are infrequent events that require very large samples and observation windows beyond twelve months. Programs can plausibly influence the upstream behaviors linked to survival, but reporting a mortality reduction inside a year usually exceeds what the data can support.

Which maternal and child health outcomes change fastest with mHealth?

Antenatal care attendance, screening coverage, referral completion, and immunization timeliness respond fastest. These are contact-driven process indicators that move within weeks to months because they depend on reminder frequency and reduced friction rather than on clinical capacity or rare clinical events.

What sample size is needed to detect a one-year impact?

It varies sharply by indicator. Process measures like attendance and coverage can show change with moderate cohorts. Mortality endpoints require very large populations, often across multiple districts, which is why most one-year evaluations focus on coverage and behavior rather than survival.

How should funders evaluate a twelve-month maternal health proposal?

Look for pre-registered short-horizon outcomes that the deployment timeline can realistically support, separated from longer-term aspirational goals. Equity-disaggregated reporting and a clear data pipeline from field to supervisor are stronger signals of credible impact than a headline mortality promise.

Circadify is working in this space alongside academic and public health partners, with a focus on the contactless screening and field-deployment data that make twelve-month outcome claims defensible. Researchers and grant-making bodies exploring collaboration or reviewing published deployment results can find research papers and partnership pathways at circadify.com/blog.